Haleon plc: Preliminary 2024
Full Year Results
27
February 2025: Haleon plc (the
"Company" or "Haleon") (LSE/NYSE: HLN) today announces its
preliminary full year results statement for the year ended 31
December 2024 is available at http://www.rns-pdf.londonstockexchange.com/rns/6119Y_1-2025-2-26.pdf.
The preliminary full year results
statement will also be available on the Haleon website
www.haleon.com/investors,
and the results have been submitted in full unedited text to the
Financial Conduct Authority's National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Dividend
Reflecting the strength of free cash flow generation during
the year, alongside strong organic profit growth, the Board is
proposing a 2024 total dividend of 6.6p per ordinary share which
represents a payout ratio of approximately 37% of 2024 adjusted
earnings (2023: 35%). This includes a final dividend of 4.6p per
ordinary share.
Subject to
shareholder approval, the final dividend will be paid on 5 June
2025 to holders of ordinary shares and US American Depositary
Shares (ADS) on the register as of 25 April 2025 (the record date).
The ex-dividend date for ordinary shares is 24 April 2025 and for
US American Depositary Shares (ADS) is 25 April 2025. For ordinary
shareholders wishing to participate in the Dividend Reinvestment
Programme (DRIP), the election deadline is 15 May 2025. The DRIP is
provided by Equiniti Financial Services Limited, more information
is available at www.shareview.co.uk/info/drip.
Presentation for analysts and
shareholders
A recorded results presentation by
Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief
Financial Officer, will be available shortly after 7am GMT (8am
CET) on 27 February 2025 and can be accessed at
www.haleon.com/investors.
This will be followed by a Q&A session at 9am GMT (10am CET).
For analysts and shareholders
wishing to ask questions on the Q&A call, please use the
dial-in details below which will have a Q&A
facility:
|
UK:
|
+44 (0) 800 358
1035
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
309530
|
An archived webcast of the Q&A call will be
available later on the day of the results and can be accessed at
www.haleon.com/investors.
This information contains regulated
information as per 6.3.7R of the Disclosure and Transparency Rules
of the Financial Conduct Authority.
Amanda
Mellor
Company
Secretary
Enquiries
|
Investors
|
Media
|
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh
Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email:
investor-relations@haleon.com
|
Email:
corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.
